Recently, a patient presenting with pancreatic neuroendocrine tumors was noted to have mutations to both SDHA and VHL, but it is unknown how potential RCC tumors would behave with this dual mutation burden [104]. This evidence concerns the gene VHL and renal cell carcinoma.